title: Mirtazapine orally disintegrating tablets versus venlafaxine extended release: a double-blind, randomized multicenter trial comparing the onset of antidepressant response in patients with major depressive disorder.
abstract: This randomized, multicenter, double-blind study was designed to compare specifically the onset of antidepressant action of mirtazapine orally disintegrating tablets (ODT) with venlafaxine extended-release (XR) formulation in outpatients with major depression. Both treatments were administered in a rapidly escalating dosing regimen. Target doses (mirtazapine ODT, 45 mg OD; venlafaxine XR, 225 mg OD) were reached by day 6 of treatment. On the primary efficacy parameter [the average of the change in HAM-D (17-item) total score on days 5, 8, 11, and 15], mirtazapine ODT was significantly superior to venlafaxine XR (P = 0.008). In addition, calculating the HAM-D score without the sleep items resulted in significant reductions in favor of mirtazapine ODT on days 8 (P = 0.006) and 11 (P = 0.037). The proportion of responders (HAM-D decrease of > or =50% from baseline) was higher in the mirtazapine ODT group on all assessment days, being significant on days 8 (P = 0.002), 11 (P = 0.004), and 22 (P = 0.027). More patients in the mirtazapine ODT group achieved remission (HAM-D total score of < or =7) up to day 29, and the difference was statistically significant on day 15 (P = 0.016). Significant differences in favor of mirtazapine ODT were evident in the CGI of change on days 8 (P = 0.019), 11 (P = 0.004), and 15 (P = 0.031), and the CGI of severity on days 8 (P = 0.014) and 11 (P = 0.033). Both treatments were well tolerated. These results indicate that mirtazapine ODT has a faster onset of antidepressant efficacy than venlafaxine XR in patients with major depressive disorder, and that this effect is independent of its sleep-improving properties.
authors.affiliation: PAS, Nürnberg, Germany. otto.benkert@t-online.de
authors.forename: Otto
authors.initials: O
authors.lastname: Benkert
authors.forename: Armin
authors.initials: A
authors.lastname: Szegedi
authors.forename: Michael
authors.initials: M
authors.lastname: Philipp
authors.forename: Ralf
authors.initials: R
authors.lastname: Kohnen
authors.forename: Claus
authors.initials: C
authors.lastname: Heinrich
authors.forename: Anja
authors.initials: A
authors.lastname: Heukels
authors.forename: Monique
authors.initials: M
authors.lastname: van der Vegte-Senden
authors.forename: Ross A
authors.initials: RA
authors.lastname: Baker
authors.forename: John H
authors.initials: JH
authors.lastname: Simmons
authors.forename: Albert-Jan
authors.initials: AJ
authors.lastname: Schutte
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000008:administration & dosage / Q000627:therapeutic use*; D003692:Delayed-Action Preparations; D003865:Major Depressive Disorder / Q000188:drug therapy*; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D006801:Humans; D008803:Mianserin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008875:Middle Aged; D000078785:Mirtazapine; D010349:Patient Compliance; D011569:Psychiatric Status Rating Scales; D013607:Tablets; D013997:Time Factors; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D003692:Delayed-Action Preparations; D013607:Tablets; D008803:Mianserin; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine